A pharmaceutical suspension formulation suitable for aerosol administration having from 0.0025 to 0.1% w/w of micronized Formoterol, or an acid addition salt thereof, from 0.1 to 5.0% w/w ethanol, HFA 134a, HFA 227 or a mixture of HFA 227 and HFA 134a, and optionally a surfactant other than a monoacetylated or diacetylated monoglyceride, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug.
This application claims the benefit of the filing date of U.S. provisional application No. 60/048,233, filed Jun. 2, 1997; also and, is a continuation of international application PCT/US97/09471, filed Jun. 2, 1997, which claims priority to Great Britain application GB 96.12297, filed Jun. 11, 1996.
A reactive and adsorptive (i.e., multi-functional protective) textile and methods for constructing and using same which possess at least chemically reactive and biocidal properties. Nanoparticles from different classes such as metal oxides, metal hydroxides, metal hydrates and POMs are incorporated into elements which can be utilized in a wide variety of protective materials. The nanoparticles may be treated to reduce water solubility or combined with halogens, alkali metals or secondary metal oxides to specifically engineer the nanoparticle to address a particular chemical or biocidal threat. In one aspect, a protective spatially-distributed biocidal interface is provided comprising a textile having interior structures, wherein protective nanoparticles bonded to said interior structures such that an article or portions of an article which are maintained in proximity to the textile are permitted to safely pass through a contaminated environment without dispersing the nanoparticles from protective proximity to the article.
A delivery device for the delivery of an agent to the mouth, nose or other bodily site of a user. The delivery device includes an aerosol canister that is actuated to expel propellant, which captures and disperses the agent. In a preferred embodiment, the propellant captures and disperses the agent into the mouth or nose of a user, and inhalation by the user directs the agent to the lungs of the user. The delivery device is particularly suitable for the treatment of bronchial asthma, respiratory conditions and for the delivery of systemically absorbed agents.
The invention relates to stabilized dispersions containing nanoparticles of use for the administration of medicaments. The dispersions comprise excipient nanoparticles, a dispersed phase comprising medicament and a continuous phase comprising propellant.
